At the 2021 edition of the Biomanufacturing World Summit series held November 15-16 in San Diego, CA, we spoke with Daniel Plotkin, the Strategic Account Director for Rapid Micro Biosystems, about how automation and rapid data analytics is transforming Quality and Quality Control for the biopharmaceutical industry, and how the latest generation of tools, tactics, and technologies is penetrating even the most stubbornly analog environments to get decision-makers the information they need faster than ever before, while also automating documentation for validation and compliance in a way that has always involved human intervention before.

--

Rapid Micro Biosystems is an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company’s flagship Growth Direct® platform automates and modernizes the antiquated, manual microbial quality control (MQC) testing workflows used in the largest and most complex pharmaceutical manufacturing operations across the globe. The Growth Direct® platform brings the quality control lab to the manufacturing floor, unlocking the power of in-line/at-the-line MQC automation to deliver faster results, greater accuracy, increased operational efficiency, better compliance with data integrity regulations, and quicker decision making that customers rely on to ensure safe and consistent supply of important healthcare products. The company is headquartered and has U.S. manufacturing in Lowell, Massachusetts, and global locations in Switzerland, Germany, and the Netherlands.

www.rapidmicrobio.com